References analysis of the Wikipedia article "Inibidor de recaptação de serotonina-noradrenalina-dopamina" in the Portuguese version

books.google.com

doi.org

dx.doi.org

Millan, MJ (2009). «Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs». Neurotherapeutics. 6: 53–77. PMC 5084256

. PMID 19110199. doi:10.1016/j.nurt.2008.10.039

Kulkarni, SK; Dhir, A (2009). «Current investigational drugs for major depression». Expert Opinion on Investigational Drugs. 18: 767–88. PMID 19426122. doi:10.1517/13543780902880850

Guiard, BP; El Mansari, M; Blier, P (2009). «Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors». Current Drug Targets. 10: 1069–84. PMID 19702555. doi:10.2174/138945009789735156

Marks, DM; Pae, CU; Patkar, AA (2008). «Triple reuptake inhibitors: The next generation of antidepressants». Current Neuropharmacology. 6: 338–43. PMC 2701280

. PMID 19587855. doi:10.2174/157015908787386078

Chen, Z; Skolnick, P (2007). «Triple uptake inhibitors: Therapeutic potential in depression and beyond». Expert Opinion on Investigational Drugs. 16: 1365–77. PMID 17714023. doi:10.1517/13543784.16.9.1365

Millan, MJ (2006). «Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application». Pharmacology & Therapeutics. 110: 135–370. PMID 16522330. doi:10.1016/j.pharmthera.2005.11.006

Perona, MT; Waters, S; Hall, FS; Sora, I; Lesch, KP; Murphy, DL; Caron, M; Uhl, GR (2008). «Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions». Behavioural Pharmacology. 19: 566–74. PMC 2644662

. PMID 18690111. doi:10.1097/FBP.0b013e32830cd80f

Perović, B; Jovanović, M; Miljković, B; Vezmar, S (2010). «Getting the balance right: Established and emerging therapies for major depressive disorders». Neuropsychiatric Disease and Treatment. 6: 343–64. PMC 2938284

. PMID 20856599. doi:10.2147/ndt.s10485

Rakofsky, JJ; Holtzheimer, PE; Nemeroff, CB (2009). «Emerging targets for antidepressant therapies». Current Opinion in Chemical Biology. 13: 291–302. PMC 4410714

. PMID 19501541. doi:10.1016/j.cbpa.2009.04.617

Belmaker, RH (2008). «The future of depression psychopharmacology». CNS Spectrums. 13: 682–7. PMID 18704023. doi:10.1017/S1092852900013766

Yang, AR; Yi, HS; Warnock, KT; Mamczarz, J; June Jr, HL; Mallick, N; Krieter, PA; Tonelli, L; et al. (2012). «Effects of the Triple Monoamine Uptake Inhibitor DOV 102,677 on Alcohol-Motivated Responding and Antidepressant Activity in Alcohol-Preferring (P) Rats». Alcoholism: Clinical and Experimental Research. 36: 863–73. PMC 3464941

. PMID 22150508. doi:10.1111/j.1530-0277.2011.01671.x

McMillen, BA; Shank, JE; Jordan, KB; Williams, HL; Basile, AS (2007). «Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat». Alcoholism: Clinical and Experimental Research. 31: 1866–71. PMID 17908267. doi:10.1111/j.1530-0277.2007.00513.x

Gardner, Eliot L.; Liu, Xinhe; Paredes, William; Giordano, Anthony; Spector, Jordan; Lepore, Marino; Wu, Kuo-Ming; Froimowitz, Mark (2006). «A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: Effects in laboratory rat models relating to addiction». Neuropharmacology. 51: 993–1003. PMID 16901516. doi:10.1016/j.neuropharm.2006.06.009

Tizzano, JP; Stribling, DS; Perez-Tilve, D; Strack, A; Frassetto, A; Chen, RZ; Fong, TM; Shearman, L; et al. (2008). «The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo3.1.0 hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity». The Journal of Pharmacology and Experimental Therapeutics. 324: 1111–26. PMID 18089843. doi:10.1124/jpet.107.133132

Basile, AS; Janowsky, A; Golembiowska, K; Kowalska, M; Tam, E; Benveniste, M; Popik, P; Nikiforuk, A; et al. (2007). «Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain». The Journal of Pharmacology and Experimental Therapeutics. 321: 1208–25. PMID 17325229. doi:10.1124/jpet.106.116483

Kim, K A; Song, W K; Park, J Y (2009). «Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects». Clinical Pharmacology & Therapeutics. 86: 511–518. ISSN 0009-9236. PMID 19693007. doi:10.1038/clpt.2009.145

Wellington K, Perry CM (2001). «Venlafaxine extended-release: a review of its use in the management of major depression». CNS Drugs. 15: 643–69. PMID 11524036. doi:10.2165/00023210-200115080-00007

Ahmadi, A; Khalili, M; Marami, S; Ghadiri, A; Nahri-Niknafs, B (2014). «Synthesis and pain perception of new analogues of phencyclidine in NMRI male mice». Mini Reviews in Medicinal Chemistry. 14: 64–71. PMID 24251803. doi:10.2174/1389557513666131119203551

Oishi R, Shishido S, Yamori M, Saeki K (fevereiro de 1994). «Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain». Naunyn-Schmiedeberg's Archives of Pharmacology. 349: 140–4. PMID 7513381. doi:10.1007/bf00169830

Sato T, Suemaru K, Matsunaga K, Hamaoka S, Gomita Y, Oishi R (maio de 1996). «Potentiation of L-dopa-induced behavioral excitement by histamine H1-receptor antagonists in mice». Japanese Journal of Pharmacology. 71: 81–4. PMID 8791174. doi:10.1254/jjp.71.81

Yeh SY, Dersch C, Rothman R, Cadet JL (setembro de 1999). «Effects of antihistamines on 3, 4-methylenedioxymethamphetamine-induced depletion of serotonin in rats». Synapse. 33: 207–17. PMID 10420168. doi:10.1002/(SICI)1098-2396(19990901)33:3<207::AID-SYN5>3.0.CO;2-8

Skolnick, P; Popik, P; Janowsky, A; Beer, B; Lippa, AS (2003). «Antidepressant-like actions of DOV 21,947: A "triple" reuptake inhibitor». European Journal of Pharmacology. 461: 99–104. PMID 12586204. doi:10.1016/S0014-2999(03)01310-4

Golembiowska, K; Kowalska, M; Bymaster, FP (2012). «Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity». Synapse. 66: 435–44. PMID 22213370. doi:10.1002/syn.21531

Tran, P; Skolnick, P; Czobor, P; Huang, NY; Bradshaw, M; McKinney, A; Fava, M (2012). «Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial». Journal of Psychiatric Research. 46: 64–71. PMID 21925682. doi:10.1016/j.jpsychires.2011.09.003

Zhang, R.; Li, X.; Shi, Y.; Shao, Y.; Sun, K.; Wang, A.; Sun, F.; Liu, W.; Wang, D. (2014). «The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats». PLoS ONE. 9: e91775. Bibcode:2014PLoSO...991775Z. PMC 3948889

. PMID 24614602. doi:10.1371/journal.pone.0091775

Delorenzo, C; Lichenstein, S; Schaefer, K; Dunn, J; Marshall, R; Organisak, L; Kharidia, J; Robertson, B; et al. (2011). «SEP-225289 serotonin and dopamine transporter occupancy: A PET study». Journal of Nuclear Medicine. 52: 1150–5. PMC 3856248

. PMID 21680689. doi:10.2967/jnumed.110.084525

Epstein, JW; Brabander, HJ; Fanshawe, WJ; Hofmann, CM; McKenzie, TC; Safir, SR; Osterberg, AC; Cosulich, DB; Lovell, FM (1981). «1-Aryl-3-azabicyclo3.1.0hexanes, a new series of nonnarcotic analgesic agents». Journal of Medicinal Chemistry. 24: 481–90. PMID 7241504. doi:10.1021/jm00137a002

Xu, Feng; Murry, Jerry A.; Simmons, Bryon; Corley, Edward; Fitch, Kenneth; Karady, Sandor; Tschaen, David (2006). «Stereocontrolled Synthesis of Trisubstituted Cyclopropanes: Expedient, Atom-Economical, Asymmetric Syntheses of (+)-Bicifadine and DOV21947». Organic Letters. 8: 3885–8. PMID 16898842. doi:10.1021/ol061650w

Beer, B; Stark, J; Krieter, P; Czobor, P; Beer, G; Lippa, A; Skolnick, P (2004). «DOV 216,303, a "triple" reuptake inhibitor: Safety, tolerability, and pharmacokinetic profile». Journal of Clinical Pharmacology. 44: 1360–7. PMID 15545306. doi:10.1177/0091270004269560

Prins, J; Westphal, KG; Korte-Bouws, GA; Quinton, MS; Schreiber, R; Olivier, B; Korte, SM (2011). «The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialysis study in olfactory bulbectomized rats». Pharmacology Biochemistry and Behavior. 97: 444–52. PMID 20934452. doi:10.1016/j.pbb.2010.10.001

Learned, S; Graff, O; Roychowdhury, S; Moate, R; Krishnan, KR; Archer, G; Modell, JG; Alexander, R; et al. (2012). «Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials». Journal of Psychopharmacology (Oxford, England). 26: 653–62. PMID 22048884. doi:10.1177/0269881111424931

Wallach J, Brandt SD (2018). «Phencyclidine-Based New Psychoactive Substances». Handb Exp Pharmacol. 252: 261–303. PMID 30105474. doi:10.1007/164_2018_124

Meltzer, PC; Butler, D; Deschamps, JR; Madras, BK (2006). «1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: A promising class of monoamine uptake inhibitors». Journal of Medicinal Chemistry. 49: 1420–32. PMC 2602954

. PMID 16480278. doi:10.1021/jm050797a

Carroll, FI; Lewin, AH; Mascarella, SW; Seltzman, HH; Reddy, PA (2012). «Designer drugs: A medicinal chemistry perspective». Annals of the New York Academy of Sciences. 1248: 18–38. Bibcode:2012NYASA1248...18C. PMID 22092008. doi:10.1111/j.1749-6632.2011.06199.x

Carnmalm, B; Rämsby, S; Renyi, AL; Ross, SB; Ogren, SO; Stjernstrom, Nils E. (1978). «Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants». Journal of Medicinal Chemistry. 21: 78–82. PMID 22757. doi:10.1021/jm00199a014

Dutta, AK; Ghosh, B; Biswas, S; Reith, ME (2008). «D-161, a novel pyran-based triple monoamine transporter blocker: Behavioral pharmacological evidence for antidepressant-like action». European Journal of Pharmacology. 589: 73–9. PMID 18561912. doi:10.1016/j.ejphar.2008.05.008

Wong DT, Bymaster FP, Engleman EA (1995). «Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication». Life Sci. 57: 411–41. PMID 7623609. doi:10.1016/0024-3205(95)00209-o

Tamiz, AP; Zhang, J; Flippen-Anderson, JL; Zhang, M; Johnson, KM; Deschaux, O; Tella, S; Kozikowski, AP (2000). «Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors». Journal of Medicinal Chemistry. 43: 1215–22. PMID 10737754. doi:10.1021/jm9905561

Deschamps, NM; Elitzin, VI; Liu, B; Mitchell, MB; Sharp, MJ; Tabet, EA (2011). «An enyne cycloisomerization approach to the triple reuptake inhibitor GSK1360707F». The Journal of Organic Chemistry. 76: 712–5. PMID 21174473. doi:10.1021/jo102098y

Micheli, F; Cavanni, P; Andreotti, D; Arban, R; Benedetti, R; Bertani, B; Bettati, M; Bettelini, L; et al. (2010). «6-(3,4-dichlorophenyl)-1-(methyloxy)methyl-3-azabicyclo4.1.0heptane: A new potent and selective triple reuptake inhibitor». Journal of Medicinal Chemistry. 53: 4989–5001. PMID 20527970. doi:10.1021/jm100481d

Bøgesø, KP; Christensen, AV; Hyttel, J; Liljefors, T (1985). «3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake». Journal of Medicinal Chemistry. 28: 1817–28. PMID 2999402. doi:10.1021/jm00150a012

Aluisio, L; Lord, B; Barbier, AJ; Fraser, IC; Wilson, SJ; Boggs, J; Dvorak, LK; Letavic, MA; et al. (2008). «In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor». European Journal of Pharmacology. 587: 141–6. PMID 18499098. doi:10.1016/j.ejphar.2008.04.008

Caldarone, BJ; Paterson, NE; Zhou, J; Brunner, D; Kozikowski, AP; Westphal, KG; Korte-Bouws, GA; Prins, J; et al. (2010). «The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties». The Journal of Pharmacology and Experimental Therapeutics. 335: 762–70. PMC 2993553

. PMID 20864506. doi:10.1124/jpet.110.174011

Wong, DT; Bymaster, FP (1978). «An inhibitor of dopamine uptake, LR5182, cis-3-(3,4-dichlorophenyl)-2-n,n-dimethylaminomethyl-bicyclo-2,2,2-octane, hydrochloride». Life Sciences. 23: 1041–7. PMID 713683. doi:10.1016/0024-3205(78)90664-1

Fuller, RW; Perry, KW; Snoddy, HD (1979). «In vivo effects of LR5182, cis-3-(3,4-dichlorophenyl)-2-n,n-dimethylaminomethyl- bicyclo-2,2,2-octane hydrochloride, an inhibitor of uptake into dopamine and norepinephrine neurons». Neuropharmacology. 18: 497–501. PMID 460546. doi:10.1016/0028-3908(79)90076-5

Wong, DT; Bymaster, FP; Reid, LR (1980). «Competitive inhibition of catecholamine uptake in synaptosomes of rat brain by rigid bicyclo-octanes». Journal of Neurochemistry. 34: 1453–8. PMID 7381469. doi:10.1111/j.1471-4159.1980.tb11225.x

Lile, JA; Wang, Z; Woolverton, WL; France, JE; Gregg, TC; Davies, HM; Nader, MA (2003). «The reinforcing efficacy of psychostimulants in rhesus monkeys: The role of pharmacokinetics and pharmacodynamics». The Journal of Pharmacology and Experimental Therapeutics. 307: 356–66. PMID 12954808. doi:10.1124/jpet.103.049825

Liang, Y; Shaw, AM; Boules, M; Briody, S; Robinson, J; Oliveros, A; Blazar, E; Williams, K; et al. (2008). «Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)». The Journal of Pharmacology and Experimental Therapeutics. 327: 573–83. PMID 18689611. doi:10.1124/jpet.108.143610

Fang, X.; Guo, L.; Jia, J.; Jin, G. Z.; Zhao, B.; Zheng, Y. Y.; Li, J. Q.; Zhang, A.; Zhen, X. C. (2013). «SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity». Acta Pharmacologica Sinica. 34: 1149–55. PMC 4003162

. PMID 23892272. doi:10.1038/aps.2013.66

Tian, JW; Jiang, WL; Zhong, Y; Meng, Q; Gai, Y; Zhu, HB; Hou, J; Xing, Y; Li, YX (2011). «Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties». Neuroscience. 196: 124–30. PMID 21925241. doi:10.1016/j.neuroscience.2011.08.064

Carroll, FI (2003). «2002 Medicinal Chemistry Division Award address: Monoamine transporters and opioid receptors. Targets for addiction therapy». Journal of Medicinal Chemistry. 46: 1775–94. PMID 12723940. doi:10.1021/jm030092d

Andreasen, Jesper T.; Redrobe, John P.; Nielsen, Elsebet Ø.; Christensen, Jeppe K.; Olsen, Gunnar M.; Peters, Dan (2013). «A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances». Neuropharmacology. 73: 183–191. ISSN 0028-3908. PMID 23748055. doi:10.1016/j.neuropharm.2013.04.060

Fehske, C. J.; Leuner, K.; Müller, W. E. (2009). «Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment». Pharmacological Research. 60: 68–73. PMID 19427589. doi:10.1016/j.phrs.2009.02.012

Mechan, Annis O.; Fowler, Ann; Seifert, Nicole; Rieger, Henry; Wöhrle, Tina; Etheve, Stéphane; Wyss, Adrian; Schüler, Göde; Colletto, Biagio (2010). «Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract». British Journal of Nutrition. 105: 1150–1163. ISSN 0007-1145. PMID 21205415. doi:10.1017/S0007114510004940

Sasaki, Kazunori; El Omri, Abdelfatteh; Kondo, Shinji; Han, Junkyu; Isoda, Hiroko (2013). «Rosmarinus officinalis polyphenols produce anti-depressant like effect through monoaminergic and cholinergic functions modulation». Behavioural Brain Research. 238: 86–94. ISSN 0166-4328. PMID 23085339. doi:10.1016/j.bbr.2012.10.010

Jin, Zeng-Liang; Gao, Nana; Zhou, Dan; Chi, Mu-Gen; Yang, Xue-Mei; Xu, Jiang-Ping (2012). «The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: Serotonin, norepinephrine and dopamine reuptake inhibitor». Pharmacology Biochemistry and Behavior. 100: 431–439. ISSN 0091-3057. PMID 22005599. doi:10.1016/j.pbb.2011.10.001

nih.gov

ncbi.nlm.nih.gov

Millan, MJ (2009). «Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs». Neurotherapeutics. 6: 53–77. PMC 5084256

. PMID 19110199. doi:10.1016/j.nurt.2008.10.039

Kulkarni, SK; Dhir, A (2009). «Current investigational drugs for major depression». Expert Opinion on Investigational Drugs. 18: 767–88. PMID 19426122. doi:10.1517/13543780902880850

Marks, DM; Pae, CU; Patkar, AA (2008). «Triple reuptake inhibitors: The next generation of antidepressants». Current Neuropharmacology. 6: 338–43. PMC 2701280

. PMID 19587855. doi:10.2174/157015908787386078

. PMID 18690111. doi:10.1097/FBP.0b013e32830cd80f

Chen, Z; Yang, J; Tobak, A (2008). «Designing new treatments for depression and anxiety». IDrugs : The Investigational Drugs Journal. 11: 189–97. PMID 18311656

. PMID 20856599. doi:10.2147/ndt.s10485

Rakofsky, JJ; Holtzheimer, PE; Nemeroff, CB (2009). «Emerging targets for antidepressant therapies». Current Opinion in Chemical Biology. 13: 291–302. PMC 4410714

. PMID 19501541. doi:10.1016/j.cbpa.2009.04.617

Belmaker, RH (2008). «The future of depression psychopharmacology». CNS Spectrums. 13: 682–7. PMID 18704023. doi:10.1017/S1092852900013766

. PMID 22150508. doi:10.1111/j.1530-0277.2011.01671.x

. PMID 24614602. doi:10.1371/journal.pone.0091775

. PMID 21680689. doi:10.2967/jnumed.110.084525

Keller, HH; Schaffner, R; Carruba, MO; Burkard, WP; Pieri, M; Bonetti, EP; Scherschlicht, R; Da Prada, M; Haefely, WE (1982). «Diclofensine (Ro 8-4650)--a potent inhibitor of monoamine uptake: Biochemical and behavioural effects in comparison with nomifensine». Advances in Biochemical Psychopharmacology. 31: 249–63. PMID 6979165

Omer, LM (1982). «Pilot trials with diclofensine, a new psychoactive drug in depressed patients». International Journal of Clinical Pharmacology, Therapy, and Toxicology. 20: 320–6. PMID 7107085

Wallach J, Brandt SD (2018). «Phencyclidine-Based New Psychoactive Substances». Handb Exp Pharmacol. 252: 261–303. PMID 30105474. doi:10.1007/164_2018_124

. PMID 16480278. doi:10.1021/jm050797a

. PMID 20864506. doi:10.1124/jpet.110.174011

. PMID 23892272. doi:10.1038/aps.2013.66

worldcat.org

Inibidor de recaptação de serotonina-noradrenalina-dopamina (Portuguese Wikipedia)

books.google.com

clinicaltrials.gov

doi.org

dx.doi.org

espacenet.com

worldwide.espacenet.com

fasebj.org

google.com

harvard.edu

ui.adsabs.harvard.edu

independent.co.uk

lundbeck.com

nih.gov

ncbi.nlm.nih.gov

semanticscholar.org

theguardian.com

webcitation.org

who.int

worldcat.org

zenodo.org